Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 9

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 9
---
 is www.medicuspharma.com. Information contained on our website is not incorporated by reference into this offering circular, and you should not consider information contained on our website to be part of this offering circular or in deciding whether to purchase our securities. Our agent for service of process in the United States is Medicus Pharma Inc.

Share Consolidation

In connection with our U.S. initial public offering, we effected a 1-for-2 consolidation, or reverse stock split (the "Share Consolidation"), of our issued and outstanding common shares. Except where otherwise indicated, all share and per share data in this offering circular have been retroactively restated to reflect the Share Consolidation.

<div align='center'>- 3 -</div>

Recent Developments

TSXV Delisting

On February 11, 2025, the Company announced that the Company's board of directors had approved the voluntary delisting of its common shares from the TSXV. The delisting was completed on February 21, 2025. The Company’s common shares will continue to be listed and trade on the Nasdaq under the symbol “MDCX”.

Standby Equity Purchase Agreement

On February 10, 2025, the Company also announced that it had entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”). Pursuant to the SEPA and subject to the satisfaction of certain conditions, Yorkville has committed to purchase the Company’s common shares, no par value, in increments (each purchase, an “Advance”) up to an aggregate gross sales price of up to $15,000,000 during the 36 months following the date of the SEPA. The common shares will be sold at the Company’s option pursuant to the SEPA at 97% of the Market Price (as defined pursuant to the SEPA) and purchases are subject to certain limitations set forth in the SEPA. The Company reserves the right to set a minimum acceptable price in connection with any Advance. The Company expects to use the net proceeds from any Advance, if any, to fund its Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch. The Company may also use the net proceeds of the SEPA to expand its exploratory phase 2 clinical trial to a pivotal trial and/or to expand its trials to cover other non-melanoma skin diseases. The Company expects to use any remaining net